Protease inhibitors: current status and future prospects.
Leung
D
D
Centre for Drug Design and Development, University of Queensland, Brisbane, Queensland 4072, Australia.
Abbenante
G
G
Fairlie
D P
DP
D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology; D003546:Cysteine Endopeptidases / Q000378:metabolism / Q000502:physiology; D015853:Cysteine Proteinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology; D008958:Models, Molecular; D011480:Protease Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D012697:Serine Endopeptidases / Q000378:metabolism / Q000502:physiology; D015842:Serine Proteinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology
D015853:Cysteine Proteinase Inhibitors; D011480:Protease Inhibitors; D015842:Serine Proteinase Inhibitors; D012697:Serine Endopeptidases; D003546:Cysteine Endopeptidases; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases